What is Dihexa?
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a cognitive-enhancing peptide derived from angiotensin IV. It is considered one of the most potent nootropic peptides discovered, showing effects up to 10 million times more potent than BDNF at enhancing synaptic connectivity in some assays.
Developed at Washington State University, Dihexa works primarily through hepatocyte growth factor (HGF) signaling and has shown remarkable results in animal models of cognitive impairment.
Discovery
Dihexa was developed by Dr. Joseph Harding's group at Washington State University while studying angiotensin IV analogs for cognitive enhancement. The goal was to create orally active, blood-brain barrier penetrant compounds.
Mechanism of Action
HGF/c-Met Pathway
Dihexa enhances cognition through:
- Potentiates HGF/c-Met signaling
- Promotes dendritic spine formation
- Enhances synaptic plasticity
- Increases neuronal connectivity
- Supports learning and memory
Potency
| Comparison | Relative Potency |
|---|---|
| Dihexa vs BDNF | ~10,000,000x |
| Dihexa vs Angiotensin IV | ~7x |
Research Findings
Animal Studies
- Reversed scopolamine-induced memory impairment
- Improved spatial learning
- Enhanced object recognition
- Effects in aged animals
- Oral bioavailability demonstrated
Potential Applications
- Alzheimer's disease research
- Cognitive aging
- Traumatic brain injury
- General nootropic effects
Administration
Notable for being:
- Orally active
- Blood-brain barrier penetrant
- Active at very low doses
- Stable enough for oral delivery
Summary
Dihexa represents a breakthrough in nootropic peptide research, with unprecedented potency through HGF pathway modulation.
Key Points:
- Classification: Nootropic peptide
- Origin: Angiotensin IV derivative
- Mechanism: HGF/c-Met potentiation
- Status: Research compound